Literature DB >> 10857964

Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy.

L Tarnow1, P Rossing, F S Nielsen, J A Fagerudd, O Poirier, H H Parving.   

Abstract

OBJECTIVE: A familial predisposition was proposed to be a determinant of the increased morbidity and mortality from cardiovascular disease in type 1 diabetic patients with diabetic nephropathy. The insertion allele of an insertion/deletion polymorphism in the ACE (ACE/ID) gene seems to protect against coronary heart disease in nondiabetic and diabetic subjects. The aim of the present study was to evaluate these hypotheses in parents of a large group of type 1 diabetic patients with and without diabetic nephropathy. RESEARCH DESIGN AND METHODS: We investigated cardiovascular morbidity and mortality of parents of 163 type 1 diabetic patients with nephropathy and parents of 163 sex- and age-matched normoalbuminuric patients with type 1 diabetes.
RESULTS: Kaplan-Meier curves showed that total parental mortality was significantly increased in parents of type 1 diabetic patients with nephropathy (121 of 244 [ approximately 50%] ) as compared with parents of normoalbuminuric type 1 diabetic patients (119 of 269 [approximately 44%]) (P = 0.008 [log-rank test]) partially due to an increase in cardiovascular deaths (48 of 244 [approximately 20%] vs. 42 of 269 [approximately 16%], P<0.05). In addition, more patients with nephropathy, as compared with the normoalbuminuric group, had at least one parent with fatal/nonfatal cardiovascular disease (46% [95% CI 38-54] vs. 36% [28-44], P = 0.05). Fathers of patients homozygous for the I-allele of the ACE/ID polymorphism had significantly less myocardial infarction as compared with other genotypes (P = 0.03), regardless of the nephropathic state of the offspring.
CONCLUSIONS: Cardiovascular morbidity and early mortality clusters in parents of type 1 diabetic patients with diabetic nephropathy The ACE/ID polymorphism helps explain the increased morbidity from cardiovascular disease.

Entities:  

Mesh:

Year:  2000        PMID: 10857964     DOI: 10.2337/diacare.23.1.30

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

1.  Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy.

Authors:  Frank A Engler; Bo Zheng; Joseph P Balthasar
Journal:  Pharm Res       Date:  2013-11-08       Impact factor: 4.200

2.  Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

Authors:  P Rossing
Journal:  Diabetologia       Date:  2005-12-09       Impact factor: 10.122

3.  Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse.

Authors:  Phyllis Chew; Derek Y C Yuen; Nada Stefanovic; Josefa Pete; Melinda T Coughlan; Karin A Jandeleit-Dahm; Merlin C Thomas; Franklin Rosenfeldt; Mark E Cooper; Judy B de Haan
Journal:  Diabetes       Date:  2010-09-07       Impact factor: 9.461

4.  Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice.

Authors:  Roy Asaf; Shany Blum; Ariel Roguin; Shiri Kalet-Litman; Jad Kheir; Avi Frisch; Rachel Miller-Lotan; Andrew P Levy
Journal:  Cardiovasc Diabetol       Date:  2009-06-02       Impact factor: 9.951

5.  Prediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers.

Authors:  Mohamed Al-Shabrawey; Sylvia Smith
Journal:  EPMA J       Date:  2010-03-23       Impact factor: 6.543

Review 6.  In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease.

Authors:  Rabea Asleh; Andrew P Levy
Journal:  Vasc Health Risk Manag       Date:  2005
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.